Compare SPRY & KBDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SPRY | KBDC |
|---|---|---|
| Founded | 2015 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | N/A | N/A |
| Metric | SPRY | KBDC |
|---|---|---|
| Price | $11.35 | $14.78 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $31.25 | $15.80 |
| AVG Volume (30 Days) | ★ 1.6M | 384.0K |
| Earning Date | 11-10-2025 | 11-10-2025 |
| Dividend Yield | N/A | ★ 12.86% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $142,772,000.00 | N/A |
| Revenue This Year | N/A | $193.84 |
| Revenue Next Year | $127.81 | $9.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 5459.66 | N/A |
| 52 Week Low | $6.66 | $13.06 |
| 52 Week High | $18.90 | $17.99 |
| Indicator | SPRY | KBDC |
|---|---|---|
| Relative Strength Index (RSI) | 62.09 | 43.21 |
| Support Level | $9.78 | $14.61 |
| Resistance Level | $11.69 | $15.65 |
| Average True Range (ATR) | 0.72 | 0.27 |
| MACD | 0.10 | -0.11 |
| Stochastic Oscillator | 82.21 | 15.46 |
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
Kayne Anderson BDC Inc is an externally managed, closed-end, non-diversified management investment company that has elected to be regulated as a business development company that invests primarily in first-lien senior secured loans, with a secondary focus on unitranche and split-lien loans to middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation primarily through debt investments in middle-market companies.